Clinical Trials
4 trialsNCT02594384 2024-08-22
LAM-002A/NHL
OrphAI Therapeutics
Phase 1 Completed
NCT04167137 2024-05-03
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
Synlogic
Phase 1 Terminated
NCT03465891 2021-01-12
Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT02729896 2020-12-23
A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1/2 Completed